Comparing VistaGen Therapeutics (VTGN) & The Competition

VistaGen Therapeutics (NASDAQ:VTGN) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare VistaGen Therapeutics to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings for VistaGen Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1	4	0	0	1.80
VistaGen Therapeutics Competitors	9869	15283	45611	1598	2.54

VistaGen Therapeutics presently has a consensus target price of $0.95, suggesting a potential upside of 405.32%. As a group, “Biotechnology” companies have a potential upside of 122.48%. Given VistaGen Therapeutics’ higher possible upside, equities research analysts clearly believe VistaGen Therapeutics is more favorable than its competitors.

Risk & Volatility

VistaGen Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics’ competitors have a beta of -1.85, indicating that their average stock price is 285% less volatile than the S&P 500.

Profitability

This table compares VistaGen Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
VistaGen Therapeutics Competitors	-12,323.33%	-195.38%	-30.39%

Earnings and Valuation

This table compares VistaGen Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
VistaGen Therapeutics	$1.27 million	-$69.68 million	-0.11
VistaGen Therapeutics Competitors	$756.66 million	$13.58 million	-19.08

VistaGen Therapeutics’ competitors have higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

VistaGen Therapeutics competitors beat VistaGen Therapeutics on 7 of the 13 factors compared.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines. Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder. The company’s pipeline has also included PH80, an intranasal therapy investigated for migraine and other neurological conditions, and PH10, an intranasal neuroactive compound studied for depressive disorders.